Barclays Boosts DaVita (NYSE:DVA) Price Target to $150.00

DaVita (NYSE:DVA) had its price objective boosted by research analysts at Barclays from $133.00 to $150.00 in a research note issued on Monday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Barclays‘s price target would indicate a potential upside of 8.86% from the company’s current price.

DVA has been the topic of several other research reports. StockNews.com raised DaVita from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 25th. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. UBS Group boosted their target price on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Finally, Truist Financial raised their price target on shares of DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research report on Tuesday, February 20th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, DaVita currently has an average rating of “Moderate Buy” and an average target price of $121.33.

DaVita Trading Up 0.7 %

Shares of DaVita stock opened at $137.79 on Monday. The company has a debt-to-equity ratio of 7.95, a current ratio of 1.43 and a quick ratio of 1.37. The business has a fifty day simple moving average of $134.15 and a two-hundred day simple moving average of $113.89. DaVita has a 1 year low of $71.51 and a 1 year high of $145.04. The company has a market capitalization of $12.08 billion, a price-to-earnings ratio of 15.66, a P/E/G ratio of 1.17 and a beta of 1.04.

DaVita (NYSE:DVA) last posted its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The company had revenue of $3.07 billion during the quarter, compared to analysts’ expectations of $3.03 billion. During the same quarter last year, the company posted $1.58 EPS. DaVita’s quarterly revenue was up 6.9% compared to the same quarter last year. Research analysts forecast that DaVita will post 9.49 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the transaction, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the sale, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the transaction, the insider now owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The disclosure for this sale can be found here. Insiders have sold 134,540 shares of company stock valued at $16,551,071 in the last ninety days. 1.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DaVita

Several large investors have recently added to or reduced their stakes in the business. Newbridge Financial Services Group Inc. bought a new position in shares of DaVita during the 4th quarter worth approximately $30,000. Principal Securities Inc. acquired a new position in shares of DaVita during the 4th quarter valued at $37,000. Hanseatic Management Services Inc. bought a new position in DaVita during the third quarter worth $36,000. GAMMA Investing LLC acquired a new stake in DaVita in the fourth quarter worth $60,000. Finally, Quent Capital LLC increased its stake in DaVita by 21.0% in the first quarter. Quent Capital LLC now owns 581 shares of the company’s stock valued at $80,000 after purchasing an additional 101 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.